P PRIMESTOCKFINDER.COM

NVO Shares Novo Resources Corp.

ASX · ASX
$0.06 +0.00% Prices as of close 2026-10-27

Last in our picks 2026-10-21 — not in the current list; analysis below is from that screen

AI software and digital transformation exposure could re-rate if commercialization milestones improve.

  • ▸Speculative technology catalyst with limited liquidity and coverage.
  • ▾Below 50-day MA (-14.06%)
  • ▾Near 52-week low (2.1% of range)

Trend: NVO is trading below the 50-day average (-17.14%), RSI 37 — neutral momentum, with a 3-month return of +3.57%.

Valuation & quality: Novo Resources Corp. trades on price-to-book 0.48; fundamentals show net margin 0.0%, return on equity -36.0%.

Our screen: WATCH (score 0) — AI software and digital transformation exposure could re-rate if commercialization milestones improve.

Computed from end-of-day data; not personal advice.

0.14 0.06 FebMarAprMayJunJulAugSepOct
Daily close, 2026-02-08 → 2026-10-25 (AUD). Range 0.06 – 0.14.
Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
-33.30%+0.00%+0.00%-12.50%-14.30%+16.70%+0.00%-14.30%
Market cap
$25.1M
EPS (ttm)
$-0.06
Price / book
0.48
Beta
0.81
Net margin
0.0%
ROE
-36.0%
Free cash flow
$1.7M
Debt / equity
0%
52-wk range
$0.06 – $0.25
Volume
160,768
Avg volume (3m)
80,556
RSI (14)
37.2
vs 50-day MA
-17.14%
1-mo return
-20.55%
3-mo return
+3.57%
Volume z-score
0.13

Novo Resources Corp., together with its subsidiaries, evaluates, acquires, explores, and develops mineral properties in Australia. The company explores for gold and copper deposits.

Sector: Basic Materials · Industry: Gold · Australia · Website

Browse: all ASX stocks · Artificial Intelligence picks · today's movers

General information only (Australia). This is general information, not financial product advice. It doesn't consider your objectives, financial situation or needs — consider its appropriateness and seek licensed advice before acting. Not a recommendation to buy or sell any financial product.

Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.